MY ABPI LOGIN
 
Improving access to new medicines and vaccines

Improving access to new medicines and vaccines so everyone in the UK can get the latest treatments.

Medicines and vaccines have played a crucial role in increasing UK life expectancy by 11 years since 1960.  Over the last 40 years, cancer survival rates have doubled, and HIV/AIDS has been transformed into a chronic, manageable condition.  We work in partnership with the UK Government, the devolved nations and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines.

Medicine pricing

How are medicines priced?

How are new medicines developed?

What was the PPRS?

What is the life cycle of a medicine?

Improving access to medicine in the UK

The future of medicine

Supply chain

Falsified Medicines Directive (FMD)

The Falsified Medicines Directive is legislation passed by the European Union Parliament, which aims to increase the security of the manufacturing and delivery of medicines across Europe and protect patients and prevent falsified medicines from entering the supply chain.

Managing medicine shortages

The Government has released a Statutory Instruments (SI) The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 No. 775 outlining the changes to be made to regulations around the use of medicines in the UK, in the event of a No-Deal EU Exit.

Counterfeiting

The ABPI has worked with SecurMed and the MHRA, as the UK National Competent Authority, to provide useful guidance and perspective to Manufacturers and Marketing Authorisation Holders.

Rare diseases

Five essential facts about rare diseases

A rare disease is officially classified as a condition that affects less than 5 in 10,000 in the general population, but smaller numbers of patients should not mean less focus on treating them.

News: Oct 2019 - ABPI response to deal for cystic fibrosis medicines

NHS England has announced it has secured an agreement with Vertex to make available all three of their UK-licensed cystic fibrosis medicines.

Blog: Jun 2019 - Medicines pricing in the UK and access to Cystic Fibrosis medicines

Dr Richard Torbett provides an ABPI view on medicines pricing in the UK and the current situation between NHS England and Vertex on access to Orkambi for Cystic Fibrosis patients

Antimicrobial resistance (AMR)

Antimicrobial resistance (AMR)

Antimicrobial resistance is a global public health issue requiring multiple solutions and a sustained, coordinated response. The pharmaceutical industry is committed to tackling AMR working alongside governments and NGOs.

News: Jun 2019 - Dame Sally Davies named UK Special Envoy on AMR

Outgoing Chief Medical Officer Professor Dame Sally Davies has been named as UK Special Envoy on antimicrobial resistance (AMR), working across all sectors including includes health, agriculture and the environment to tackle the global health threat.

Blog: Feb 2019 - Fighting AMR by stopping infections before they start

Preventing infections will help us get antimicrobial resistance (AMR) under control, according to a new plan from the UK Government.

Working with the NHS

Joint Working - a toolkit for industry and the NHS

New guidance to help the NHS and the pharmaceutical industry work successfully together. 

A new ambition for cross-sector collaboration

The UK Life Sciences Industrial Strategy should be required reading for every healthcare leader in the UK. It makes clear that the NHS must be an active participant with industry in delivering the shared objective of outstanding patient outcomes.

Simplifying cross-sector working between NHS Integrated Care Systems

This guidance has been developed by the AHSN Network and the ABPI.

Vaccines

Vaccines

Vaccination has saved more lives and prevented more serious diseases than any advance in recent medical history. Every year, 2 – 3 million lives are saved across the world because of immunisation.

Public health benefit of vaccination

Only clean water rivals vaccines at reducing infectious diseases and deaths1. Immunisation has the potential to prevent 6 million deaths worldwide each year2.

News: Jun 2019 - No changes to cost-effectiveness test for vaccination programmes

The ABPI welcomes the news of the Government’s decision to reject three significant recommendations made by the Cost-Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP) group